A sub-analysis of serum samples from 142 patients in the Rituximab for ANCA-associated Vasculitis (RAVE) trial showed total cholesterol and LDL-C increased in the 6 months following diagnosis, particularly for patients with a new diagnosis or those with PR3-positive AAV [24]. The gene discussed is PRTN3; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.